Cyclic peptides occupy a unique space in drug discovery, offering advantages of both small molecule drugs (oral bioavailability potential, cell permeability) and biologics (high target selectivity, ability to disrupt protein-protein interactions). This guide explores cyclic peptide chemistry, applications, and their emerging role in addressing challenging therapeutic targets.
Why Cyclic Peptides?
The Limitations of Linear Peptides
Linear peptides face several challenges as therapeutics:
Rapid proteolytic degradationPoor membrane permeabilityConformational flexibility reducing binding selectivityShort half-lives requiring frequent dosingGenerally limited to extracellular targetsCyclization Advantages
Constraining peptides into cyclic structures addresses many of these limitations:
Proteolytic stability: No free termini for exopeptidases; constrained backbone resists endopeptidasesConformational constraint: Pre-organized binding conformation improves selectivity and affinityMembrane permeability: Reduced polarity through intramolecular hydrogen bondingImproved pharmacokinetics: Longer half-lives than linear counterpartsTypes of Cyclization
Head-to-Tail Cyclization
The C-terminus is linked to the N-terminus through an amide bond:
Creates macrocyclic lactamEliminates terminal chargesExamples: Cyclosporine A, many natural cyclic peptidesSide Chain-to-Side Chain Cyclization
Linkages between amino acid side chains:
Disulfide bridges: Cys-Cys bonds (most common natural cyclization)Lactam bridges: Lys-Glu or Lys-Asp linkagesThioether bridges: Cys to dehydrated Ser/Thr (found in lantibiotics)Side Chain-to-Terminus
Side chain linked to N- or C-terminusCommon in synthetic peptidesProvides structural flexibility in designStapled Peptides
Hydrocarbon staples across i, i+4 or i, i+7 positions:
Stabilize alpha-helical conformationsImprove cell penetrationParticularly useful for intracellular PPI targetsNatural Cyclic Peptide Examples
Cyclosporine A
11-amino acid cyclic peptide from fungusContains N-methylated residuesImmunosuppressant targeting cyclophilinOral bioavailability despite large sizeVancomycin
Glycopeptide antibioticComplex macrocyclic structure with multiple ringsTargets bacterial cell wall synthesisDaptomycin
Cyclic lipopeptide antibiotic13-amino acid ring with lipid tailTargets bacterial membraneConotoxins
Disulfide-rich peptides from cone snailsMultiple cyclization patternsHighly selective ion channel modulatorsDesign Principles for Cyclic Peptides
Ring Size Considerations
Small rings (5-8 residues): Highly constrained, limited conformational spaceMedium rings (9-14 residues): Balance of constraint and flexibilityLarge rings (15+ residues): More flexible, may require additional constraintsAchieving Membrane Permeability
The "rule of five" doesn't apply to cyclic peptides. Factors promoting permeability:
N-methylation of backbone amidesIntramolecular hydrogen bondingLipophilic side chainsAppropriate ring size (typically 6-10 residues)Conformational flexibility in solution, rigidity in membraneMaintaining Activity
Identify minimal binding epitope before cyclizationPosition cyclization linkage away from binding interfaceConsider conformational requirements of target interactionUse structure-activity relationships to optimizeSynthetic Approaches
Solution-Phase Cyclization
Linear precursor synthesized on solid phaseCleaved and cyclized in dilute solutionDilution minimizes oligomerizationSuitable for head-to-tail cyclizationOn-Resin Cyclization
Side chain anchored to resinCyclization performed while still attachedPseudo-dilution effect reduces oligomersEfficient for certain cyclization typesNative Chemical Ligation
For larger cyclic peptidesThioester and N-terminal Cys reactEnables synthesis of sequences too long for direct SPPSEnzymatic Cyclization
Sortase A, butelase, othersSite-specific, efficientRequires recognition sequencesResearch Applications
Protein-Protein Interaction (PPI) Inhibitors
Cyclic peptides excel at disrupting PPIs:
Large binding surfaces accessibleHigh selectivity achievableCan target "undruggable" interactionsReceptor Agonists and Antagonists
GPCR-targeting cyclic peptidesIntegrin inhibitors (e.g., cilengitide)Growth factor receptor modulatorsEnzyme Inhibitors
Protease inhibitorsKinase inhibitors (emerging area)Conformationally constrained substrate mimicsTargeting Intracellular Proteins
Stapled peptides and other cell-permeable cyclics:
p53-MDM2 interactionBcl-2 family proteinsTranscription factor interactionsTherapeutic Development Landscape
Approved Cyclic Peptide Drugs
Cyclosporine: ImmunosuppressionDaptomycin: Gram-positive infectionsRomidepsin: Cancer (HDAC inhibitor)Pasireotide: Cushing's diseaseVoclosporin: Lupus nephritis (cyclosporine derivative)Clinical Pipeline
Active development across:
Oncology (PPI disruptors)Infectious disease (novel mechanisms)Metabolic disease (GLP-1 analogs)Cardiovascular (integrin targeting)Immunology (immune checkpoint modulators)Practical Research Considerations
Synthesis and Purification Challenges
Cyclization efficiency varies by sequenceEpimerization risk during cyclizationMultiple conformational isomers possibleHPLC purification may require optimizationCharacterization Requirements
Mass spectrometry for identityNMR for conformation analysisHPLC for purity and potential isomersFunctional assays to confirm activityStability Considerations
Generally more stable than linear counterpartsMay still require careful storageSolution stability should be assessedConclusion
Cyclic peptides represent one of the most exciting frontiers in drug discovery, offering solutions to previously intractable targets while maintaining drug-like properties. Understanding the principles of cyclic peptide design, synthesis, and characterization enables researchers to leverage these unique molecules for both basic research and therapeutic development.